characteristics.text: ERC000011
characteristics.characteristic: ENA-CHECKLIST
characteristics.text: 2022-03-14T00:28:36Z
characteristics.characteristic: ENA-FIRST-PUBLIC
characteristics.text: 2022-03-14T00:28:36Z
characteristics.characteristic: ENA-LAST-UPDATE
characteristics.text: SAMEA13259309
characteristics.characteristic: External Id
characteristics.text: ETH ZURICH
characteristics.characteristic: INSDC center name
characteristics.text: 2022-03-14T00:28:36Z
characteristics.characteristic: INSDC first public
characteristics.text: 2022-03-14T00:28:36Z
characteristics.characteristic: INSDC last update
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS10862286
characteristics.characteristic: SRA accession
characteristics.text: E-MTAB-11511:Sample 6
characteristics.characteristic: Submitter Id
characteristics.text: 8
characteristics.unit: week
characteristics.characteristic: age
characteristics.text: ArrayExpress
characteristics.ontologyTerms: http://www.ebi.ac.uk/efo/EFO_0009737
characteristics.characteristic: broker name
characteristics.text: T cell
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/CL_0000084
characteristics.characteristic: cell type
characteristics.text: house mouse
characteristics.characteristic: common name
characteristics.text: Protocols: CD8 T cells were isolated via FACS seven days post addition of tamoxifen. We employed intracranial (i.c.) infection of adult GFAP:GP mice with rLCMV-GP33 as an experimental model of transient viral infection of the brain to generate GP33-specific tissue-resident memory CD8+ T cells (TRM). Cross-reactivity of TRM with a CNS-restricted self-antigen was modeled by the TAM-inducible expression of LCMV glycoprotein (GP) antigens in a CNS-restricted cell population (astrocytes). For depletion of circulating CD8+ T cells or CD4+ T cells, mice were treated intraperitoneally twice over a 3 days interval with 200 μg of rat-anti-mouse-CD8α-depleting antibody (BioXCell, BE0117), 250 μg of rat-anti-mouse-CD4 -depleting antibody (home-made, clone YTS191) or isotype control (BioXCell, BE0090).Anti-CD8 was administered 7 and 4 days before start of TAM while anti-CD4 was administered 4 and 1 day prior start of TAM. For relapse experiments, mice were treated intraperitoneally with 200 μg of mouse-anti-mouse-CD8α -depleting antibody (Ab00166-2.0, Absolute Antibody) or isotype control (Ab00166-2.3, Absolute Antibody) 7 and 4 days before each TAM administration. According to 10x 3' protocol According to 10x 3' protocol
characteristics.characteristic: description
characteristics.text: adult
characteristics.characteristic: developmental stage
characteristics.text: Stop-GPflox
characteristics.characteristic: genotype
characteristics.text: Mus musculus
characteristics.characteristic: organism
characteristics.text: Mus musculus
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_10090
characteristics.characteristic: organism
characteristics.text: brain
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/UBERON_0000955
characteristics.characteristic: organism part
characteristics.text: Mus musculus
characteristics.characteristic: scientific_name
characteristics.text: male
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/PATO_0000384
characteristics.characteristic: sex
characteristics.text: StopGP - no TAM reactivation
characteristics.characteristic: stimulus
characteristics.text: C57BL6
characteristics.ontologyTerms: http://www.ebi.ac.uk/efo/EFO_0004472
characteristics.characteristic: strain
characteristics.text: Sample 6
characteristics.characteristic: title